Roquefort Therapeutics Past Earnings Performance
Past criteria checks 0/6
Roquefort Therapeutics has been growing earnings at an average annual rate of 5.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 100% per year.
Key information
5.7%
Earnings growth rate
-3.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -100.0% |
| Return on equity | -31.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Roquefort Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -2 | 1 | 0 |
| 31 Mar 24 | 0 | -2 | 1 | 0 |
| 31 Dec 23 | 0 | -2 | 2 | 1 |
| 30 Sep 23 | 0 | -2 | 2 | 1 |
| 30 Jun 23 | 0 | -2 | 2 | 1 |
| 31 Mar 23 | 0 | -2 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 0 | 0 |
| 31 Dec 21 | 0 | -1 | 0 | 0 |
Quality Earnings: ROQA.F is currently unprofitable.
Growing Profit Margin: ROQA.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ROQA.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ROQA.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ROQA.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ROQA.F has a negative Return on Equity (-31.28%), as it is currently unprofitable.